

This is a countywide group covering NHS Derby & Derbyshire Integrated Care Board, Derbyshire Community Health Service Foundation Trust, Derbyshire Healthcare Foundation Trust, University Hospital of Derby and Burton and Chesterfield Royal Hospital foundation trusts. It provides recommendations on the prescribing and commissioning of drugs
See <http://www.derbyshiremedicinesmanagement.nhs.uk/home>

Key Messages from January's JAPC meeting

The JAPC Prescribing Specification for 2025-26 has been produced & agreed and can be found [here](#).

Key new drug traffic light additions/changes

The traffic light classification for indapamide, a thiazide-like diuretic, has been changed to **GREEN** for the immediate release preparation, this brings our Derbyshire formulary in line with the NICE Hypertension Guideline [NG136](#). Previously bendroflumethiazide was the first choice diuretic for hypertension in Derbyshire as historically it was more cost effective. Indapamide Modified-Release tablets remain **GREY** as they are a less cost effective option and not included in the NICE guideline.

The Derbyshire JAPC Guideline Management of Hypertension using ABPM is in the process of being updated.

MHRA

Due to the national shortage of Pancreatic enzyme replacement therapy (PERT) the MHRA has released another NatPSA which can be found [here](#). This guidance is aimed at providing assistance for those prescribers experiencing problems getting hold of PERT for their patients.

Traffic light changes

Drug	Decision	Details
Indapamide tablets	GREEN	Immediate release preparation only
Indapamide MR	GREY	No change
Bevacizumab gamma	RED	as per NICE TA1022. NHSE commissioned.
Elranatamab	RED	as per NICE TA1023. NHSE commissioned.
Ublituximab	RED	as per NICE TA1025. NHSE commissioned.
Tirzepatide	RED	as per NICE TA1026 for managing overweight and obesity in adults
Donanemab (Kisunla)	DNP	Not approved by NICE
Toripalimab	DNP	NICE TA1024 (terminated appraisal)
Crizotinib	RED	As per NICE TA1021: NHSE commissioned.

DERBYSHIRE MEDICINES MANAGEMENT, PRESCRIBING AND GUIDELINES WEBSITE

This website is the first port of call for information on local NHS decisions and guidance on medicines use. It includes local prescribing formularies, JAPC decisions, traffic lights, shared care guidelines, medicines guidelines, newsletters, controlled drug resources, and other medicines management resources. The site improves upon previous sites in several ways. It is faster, more reliable, has its own search engine, and it is easier to find information. Content is constantly being updated and you can sign up for e-mail alerts to keep you up to date.

Definitions:

RED: drugs are those where prescribing responsibility lies with a hospital consultant or a specialist.

AMBER: drugs are those that although usually initiated within a hospital setting, could appropriately become the responsibility of the GP, under a shared care agreement.

GREEN*: drugs are regarded as suitable for primary care prescribing.

GREY*: drugs are those that JAPC does not recommend for use, except in exceptional circumstances, due to lack of data on safety, effectiveness, and/or cost-effectiveness.

Do Not Prescribe (DNP)*: drugs, treatments or medical devices are **not** recommended or commissioned* (*unless agreed through the individual funding request route)

CONSULTANT/SPECIALIST INITIATION: consultant/specialist issues the first prescription usually following a consultation because:

- a. The patient requires specialist assessment before starting treatment and/ or
- b. Specialist short term assessment of the response to the drug is necessary.

GPs will be asked to continue prescribing when the patient is stable or predictably stable

CONSULTANT/SPECIALIST RECOMMENDATION: consultant/specialist requests GPs prescribe initial and on-going prescriptions, but ensures:

- a. There is no immediate need for the treatment and is line with discharge policies and
- b. The patient response to the treatment is predictable and safe